Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the bodyâs own machinery â the T-cell â to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patientâs own T-cells to express our SPEAR TCRs to target and potentially destroy tumors. Source
No articles found.
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunot...
IMV Inc. is a clinical stage biopharmaceutical ...
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a clinical stage biopharmaceutical com...
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a c...
Intercept is a biopharmaceutical company focused on the development and commercial...
Intercept is a biopharmaceutical company focuse...
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inha...
Pulmatrix is a clinical stage biopharmaceutical...
We are a vertically integrated commercial biopharmaceutical company that develops,...
We are a vertically integrated commercial bioph...
HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a new...
HOOKIPA Pharma Inc. is a clinical stage biophar...
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing ...
Trillium Therapeutics Inc. is a clinical stage ...
Join the National Investor Network and get the latest information with your interests in mind.